Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.
Andrew BottomleyMadeline PeJeff SloanEthan BaschFranck BonnetainMelanie CalvertAlicyn CampbellCharles CleelandKim CocksLaurence ColletteAmylou C DueckNancy DevlinHans-Henning FlechtnerCarolyn GotayEva GreimelIngolf GriebschMogens GroenvoldJean-Francois HamelMadeleine KingPaul G KluetzMichael KollerDaniel C MaloneFrancesca MartinelliSandra A MitchellCarol M MoinpourJammbe Z MusoroDaniel O'ConnorKathy OliverElisabeth Piault-LouisMartine PiccartFrancisco L PimentelChantal QuintenJaap C ReijneveldChristoph SchürmannAshley Wilder SmithKatherine M SoltysRajeshwari SridharaMartin J B TaphoornGalina VelikovaCorneel CoensPublished in: Clinical trials (London, England) (2018)
The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad Consortium membership which includes regulators, patients, clinicians, and academics.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical practice
- chronic kidney disease
- open label
- double blind
- peritoneal dialysis
- phase iii
- randomized controlled trial
- transcription factor
- phase ii
- squamous cell carcinoma
- squamous cell
- artificial intelligence
- quality improvement
- study protocol